Study finds drug-eluting stents exhibit some benefits over bare-metal stents in patients over 80, though both demonstrat

Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Patients over the age of 80 are often excluded from randomized clinical trials, but this age group represents an increasing proportion of the daily revascularization workload, and in fact the fastest growing segment of the population. Octogenarians are more likely to present with complex coronary disease, anatomically expectant of drug- eluting stenting (DES). However, these same patients are at higher risk of bleeding complications from prolonged dual (DAPT).

XIMA is an international, multicenter, to examine the safety and efficacy outcomes among with either a bare-metal stent (BMS) or drug-eluting (DES) for complex coronary disease in the context of stable angina or an acute coronary syndrome. were excluded.

The trial enrolled 800 patients aged 80 or above who underwent angiography for stable angina or following an . If the coronary narrowing was deemed suitable for stenting and the lesion was either ≥15mm long and/or ≤3mm diameter, the patient was randomized to receive either BMS or DES. As long as stent deployment was considered feasible, there were no anatomical exclusions to the trial, which could include chronic total occlusions, bifurcations, severe calcification and left main stem lesions.

The primary endpoint of major adverse cardiac events (MACE) occurred in 18.7 percent of the BMS patients and 14.5 percent of the DES patients (p=0.092). Target vessel revascularization was 7 percent in the BMS group and 2 percent in the DES group (p=0.0009). Heart attack occurred in 8.7 percent of the BMS patients and 4.3 percent of the DES patients (p=0.01). There was no difference in mortality between the two groups at one year (7.2 percent vs. 8.5 percent, p=0.5) and no difference in the rates of major bleeding (1.7 percent vs. 2.3 percent, p=0.61).

"Results of the XIMA trial indicate that in patients over the age of 80, bare-metal and drug-eluting stents both offer good clinical results. Overall, patients who received drug-eluting stents experienced less major adverse cardiac events," said lead investigator Adam J. de Belder, MD. Dr. de Belder is Director of the Cardiac Catheter Laboratories at Brighton and Sussex University Hospitals in the United Kingdom.

"There were no differences in mortality between the two groups at one year and no difference in the rates of major bleeding, despite different dual antiplatelet therapy regimes. However there were significantly lower rates of target vessel revascularisation and myocardial infarction among DES-treated patients," said Dr. de Belder.

add to favorites email to friend print save as pdf

Related Stories

Results of the DEB-AMI Trial reported at TCT 2011

Nov 10, 2011

A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Drug eluting stents used less often in women than men

Aug 27, 2012

Drug eluting stents (DES) are used less often in women treated with percutaneous coronary intervention (PCI) for coronary artery disease than men treated with PCI for the same condition, according to research presented today, ...

Results of the TWENTE trial reported at TCT 2011

Nov 11, 2011

The TWENTE clinical trial, which compared two second generation drug-eluting stents – zotarolimus and everolimus-eluting stents – established non-inferiority between the two stents as measured by the primary endpoint: ...

Recommended for you

NT-proBNP modestly improves CVD risk prediction in women

Oct 24, 2014

(HealthDay)—N-terminal pro-B-type natriuretic peptide (NT-proBNP) modestly improves cardiovascular disease (CVD) risk prediction for women, according to a study published in the Oct. 28 issue of the Journal of ...

User comments